Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
In the latest session, Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) closed at $65.69 down -7.23% from its previous closing price of $70.81. In other words, the price has decreased by -$7.23 from its previous closing price. On the day, 7.16 million shares were traded. ARWR stock price reached its highest trading level at $67.34 during the session, while it also had its lowest trading level at $63.0.
Ratios:
For a deeper understanding of Arrowhead Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.70 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 56.86. For the most recent quarter (mrq), Quick Ratio is recorded 4.86 and its Current Ratio is at 4.86. In the meantime, Its Debt-to-Equity ratio is 1.57 whereas as Long-Term Debt/Eq ratio is at 1.47.
Upgrades & Downgrades
In the most recent recommendation for this company, Goldman on June 05, 2024, initiated with a Neutral rating and assigned the stock a target price of $31.
On December 04, 2023, BofA Securities started tracking the stock assigning a Buy rating and target price of $29.
On September 19, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $33.Citigroup initiated its Neutral rating on September 19, 2023, with a $33 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 05 ’26 when O’Brien Patrick sold 49,493 shares for $63.11 per share. The transaction valued at 3,123,349 led to the insider holds 474,908 shares of the business.
Hamilton James C sold 40,164 shares of ARWR for $2,534,661 on Jan 05 ’26. The Chief Medical Officer now owns 171,958 shares after completing the transaction at $63.11 per share. On Jan 02 ’26, another insider, Anzalone Christopher Richard, who serves as the Chief Executive Officer of the company, sold 13,187 shares for $66.10 each. As a result, the insider received 871,703 and left with 3,792,739 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARWR now has a Market Capitalization of 8925935616 and an Enterprise Value of 8785209344. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.76 while its Price-to-Book (P/B) ratio in mrq is 19.13. Its current Enterprise Value per Revenue stands at 10.592 whereas that against EBITDA is 71.849.
Stock Price History:
The Beta on a monthly basis for ARWR is 1.22, which has changed by 2.8296375 over the last 52 weeks, in comparison to a change of 0.19182634 over the same period for the S&P500. Over the past 52 weeks, ARWR has reached a high of $76.76, while it has fallen to a 52-week low of $9.57. The 50-Day Moving Average of the stock is 19.83%, while the 200-Day Moving Average is calculated to be 127.07%.
Shares Statistics:
For the past three months, ARWR has traded an average of 2.40M shares per day and 1897910 over the past ten days. A total of 135.70M shares are outstanding, with a floating share count of 125.92M. Insiders hold about 7.28% of the company’s shares, while institutions hold 81.17% stake in the company. Shares short for ARWR as of 1765756800 were 10234550 with a Short Ratio of 4.26, compared to 1763078400 on 11596104. Therefore, it implies a Short% of Shares Outstanding of 10234550 and a Short% of Float of 9.7799994.
Earnings Estimates
. The current assessment of Arrowhead Pharmaceuticals Inc (ARWR) involves the perspectives of 7.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.87, with high estimates of $0.43 and low estimates of -$1.49.
Analysts are recommending an EPS of between -$1.55 and -$5.93 for the fiscal current year, implying an average EPS of -$3.49. EPS for the following year is -$4.9, with 7.0 analysts recommending between -$2.98 and -$6.77.
Revenue Estimates
A total of 9 analysts believe the company’s revenue will be $225.66M this quarter.It ranges from a high estimate of $425.29M to a low estimate of $9M. As of . The current estimate, Arrowhead Pharmaceuticals Inc’s year-ago sales were $2.5MFor the next quarter, 9 analysts are estimating revenue of $58.39M. There is a high estimate of $209M for the next quarter, whereas the lowest estimate is $1.8M.
A total of 12 analysts have provided revenue estimates for ARWR’s current fiscal year. The highest revenue estimate was $599.56M, while the lowest revenue estimate was $86M, resulting in an average revenue estimate of $393.51M. In the same quarter a year ago, actual revenue was $829.45MBased on 10 analysts’ estimates, the company’s revenue will be $261.92M in the next fiscal year. The high estimate is $377.6M and the low estimate is $114.2M.
